In a refreshing turn of events, the horizon for medical technology companies seems to be brightening with two Bain-backed cardiac medical device makers gearing up to go public this year. Kestra Medical Technologies and Heartflow, pioneers in producing non-invasive cardiac tests for heart patients, are poised to make a significant splash in the market, potentially ending the dry spell in medical technology IPOs.
- Timeline for IPOs:
- Both Kestra and Heartflow have enlisted the expertise of advisers to pave the way for their initial public offerings, with the possibility of launching in the first half of this year.
- While there is a chance of delays in the IPO timeline, the current momentum suggests a positive outlook for these companies.
- Public Listing Details:
- Bank of America has been selected to lead Kestra Medical Technologies in their public listing endeavors.
- On the other hand, Heartflow is collaborating with JPMorgan to navigate the complexities of going public.
Public investors’ hesitation towards medical device makers due to high interest rates and poor performance in the past may be shifting. The market sentiment seems to be evolving, creating a window of opportunity for innovative companies like Kestra and Heartflow.
The possibility of both companies going public could be a game-changer for a sector that has been lacking in new listings in recent years. With only four medical device makers going public in the US since the beginning of 2022, the entry of Kestra and Heartflow could inject fresh energy and investment opportunities into the industry.
The significance of these potential IPOs is underscored by Heartflow’s revolutionary product, the first non-invasive device for diagnosing coronary artery disease. This breakthrough innovation aims to cater to the needs of millions of Americans affected by heart conditions, highlighting the transformative impact the company could have on the healthcare landscape.
As venture backers await the outcome of these IPOs, the backing of prominent investors like Bain, T Rowe Price, Baillie Gifford, and Wellington Management bodes well for the future of these companies. Bain’s track record in investing in healthcare technologies signals a shift towards a more diversified landscape, away from the monopolistic stronghold often associated with West Coast venture capital funds.
In the ever-evolving landscape of medical technology, the potential IPOs of Kestra and Heartflow offer a glimpse into the future of innovative solutions for patients and investors alike. As these companies take the plunge into the public market, the ripple effects of their success could reverberate throughout the industry, setting the stage for a new era of growth and advancement.
Leave feedback about this